Cell-surface enzymes in control of leukocyte trafficking

Nature Reviews Immunology

Volumn 5, Issue 10, 2005, Pages 760-771

  Salmi, Marko ^a,b,c   Jalkanen, Sirpa ^a,b,c  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; CELL ENZYME; CHEMOATTRACTANT; CHEMOKINE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIPROTIN A; ENZYME INHIBITOR; INTEGRIN; MEMBRANE ENZYME; MEMBRANE PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NUCLEOTIDASE; OXIDOREDUCTASE; PEPTIDASE; PROTEINASE; SELECTIN; VASCULAR ADHESION PROTEIN 1;

CATALYSIS; CELL INTERACTION; CELL MEMBRANE; CELL MIGRATION; CELL SURFACE; ENDOTHELIUM CELL; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME MECHANISM; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INFLAMMATION; LEUKOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

ANIMALS; CELL ADHESION MOLECULES; CELL MEMBRANE; CHEMOTAXIS, LEUKOCYTE; ENDOTHELIUM, VASCULAR; HUMANS;

EID: 25844523991     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1705     Document Type: Review

References (135)

1. von Andrian, U. H. & Mempel, T. R. Homing and cellular traffic in lymph nodes. Nature Rev. Immunol. 3, 867-878 (2003).
2. Muller, W. A. Leukocyte-endothelial-cell interactions in leukocyte transmigration and the inflammatory response. Trends Immunol. 24, 327-334 (2003).
3. Ley, K. & Kansas, G. S. Selectins in T-cell recruitment to non-lymphoid tissues and sites of inflammation. Nature Rev. Immunol. 4, 325-335 (2004).
4. Pribila, J. T., Quale, A. C., Mueller, K. L. & Shimizu, Y. Integrins and T cell-mediated immunity. Annu. Rev. Immunol. 22, 157-180 (2004).
5. Kunkel, E. J. & Butcher, E. C. Chemokines and the tissue-specific migration of lymphocytes. Immunity 16, 1-4 (2002).
6. Moser, B., Wolf, M., Walz, A. & Loetscher, P. Chemokines: multiple levels of leukocyte migration control. Trends Immunol. 25, 75-84 (2004).
7. Di Virgilio, F. et al. Nucleotide receptors: an emerging family of regulatory molecules in blood cells. Blood 97, 587-600 (2001).
8. Goding, J. W. & Howard, M. C. Ecto-enzymes of lymphoid cells. Immunol. Rev. 161, 5-10 (1998).
9. Seman, M., Adriouch, S., Haag, F. & Koch-Nolte, F. Ecto-ADP-ribosyltransferases (ARTs): emerging actors in cell communication and signaling. Curr. Med. Chem. 11, 857-872 (2004).
10. Jalkanen, S. & Salmi, M. Cell surface monoamine oxidases: enzymes in search of a function. EMBO J. 20, 3893-3901 (2001).
11. Sedo, A. & Malik, R. Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities? Biochim. Biophys. Acta 1550, 107-116 (2001).
12. Schuber, F. & Lund, F. E. Structure and enzymology of ADP-ribosyl cyclases: conserved enzymes that produce multiple calcium mobilizing metabolites. Curr. Mol. Med. 4, 249-261 (2004).
13. -/- mice, and it shows the potential of chemical inhibitors of CD26 for the manipulation of cell migration in vivo.
14. Partida-Sanchez, S. et al. Cyclic ADP-ribose production by CD38 regulates intracellular calcium release, extracellular calcium influx and chemotaxis in neutrophils and is required for bacterial clearance in vivo. Nature Med. 7, 1209-1216 (2001). This paper shows that, in vivo, the absence of CD38 impairs leukocyte trafficking as a consequence of defects in chemotaxis.
15. Eltzschig, H. K. et al. Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: coordination by extracellular nucleotide metabolism. Blood 104, 3986-3992 (2004). This work shows that an increase in leukocyte infiltration occurs under hypoxic conditions in CD73-deficient mice.
16. Stolen, C. M. et al. Absence of the endothelial oxidase AOC3 leads to abnormal leukocyte traffic in vivo. Immunity 22, 105-115 (2005). This report describes the importance of VAP1 in leukocyte migration under physiological and pathological conditions.
17. Lazarawski, E. R., Boucher, R. C. & Harden, T. K. Mechanisms of release of nucleotides and integration of their action as P2X- and P2Y-receptor activating molecules. Mol. Pharmacol. 64, 785-795 (2003).
18. Ralevic, V. & Burnstock, G. Receptors for purines and pyrimidines. Pharmacol. Rev. 50, 413-492 (1998).
19. MacKenzie, A. et al. Rapid secretion of interleukin-1β by microvesicle shedding. Immunity 15, 825-835 (2001).
20. Idzko, M. et al. Nucleotides induce chemotaxis and actin polymerization in immature but not mature human dendritic cells via activation of pertussis toxin-sensitive P2y receptors. Blood 100, 925-932 (2002).
21. 2n receptors. Annu. Rev. Immunol. 22, 657-682 (2004).
22. Dombrowski, K. E., Ke, Y., Brewer, K. A. & Kapp, J. A. Ecto-ATPase: an activation marker necessary for effector cell function. Immunol. Rev. 161, 111-118 (1998).
23. Goepfert, C. et al. Disordered cellular migration and angiogenesis in cd39-null mice. Circulation 104, 3109-3115 (2001). This study shows that CD39-deficient monocytes and macrophages have impaired transmigration in vitro and diminished influx to angiogenic sites in vivo.
24. Guckelberger, O. et al. Beneficial effects of CD39/ectonucleoside triphosphate diphosphohydrolase-1 in murine intestinal ischemia-reperfusion injury. Thromb. Haemost. 91, 576-586 (2004).
25. Mizumoto, N. et al. CD39 is the dominant Langerhans cell-associated ecto-NTPDase: modulatory roles in inflammation and immune responsiveness. Nature Med. 8, 358-365 (2002).
26. Airas, L., Salmi, M. & Jalkanen, S. Lymphocyte-vascular adhesion protein-2 is a novel 70-kDa molecule involved in lymphocyte adhesion to vascular endothelium. J. Immunol. 151, 4228-4238 (1993).
27. Airas, L. et al. CD73 is involved in lymphocyte binding to the endothelium: characterization of lymphocyte-vascular adhesion protein 2 identifies it as CD73. J. Exp. Med. 182, 1603-1608 (1995).
28. Resta, R., Yamashita, Y. & Thompson, L. F. Ecto-enzyme and signaling functions of lymphocyte CD73. Immunol. Rev. 161, 95-109 (1998).
29. 2 integrins and L-selectin of human polymorphonuclear leukocytes in vitro. J. Leukoc. Biol. 59, 671-682 (1996).
30. 9 receptors. J. Immunol. 148, 2201-2206 (1992).
31. Ohta, A. & Sitkovsky, M. Role of G-protein-coupled adenosine receptors in down regulation of inflammation and protection from tissue damage. Nature 414, 916-920 (2001).
32. Bouma, M. G., van den Wildenberg, F. A. & Buurman, W. A. Adenosine inhibits cytokine release and expression of adhesion molecules by activated human endothelial cells. Am. J. Physiol. 270, C522-C529 (1996).
33. Comerford, K. M., Lawrence, D. W., Synnestvedt, K., Levi, B. P. & Colgan, S. P. Role of vasodilator-stimulated phosphoprotein in PKA-induced changes in endothelial junctional permeability. FASEB J. 16, 583-585 (2002).
34. Thompson, L. F. et al. Crucial role for ecto-5′-nucleotidase (CD73) in vascular leakage during hypoxia. J. Exp. Med. 200, 1395-1405 (2004).
35. Niemela, J. et al. IFN-α induced adenosine production on the endothelium: a mechanism mediated by CD73 (ecto-5′-nucleotidase) up-regulation. J. Immunol. 172, 1646-1653 (2004).
36. Airas, L., Niemela, J. & Jalkanen, S. CD73 engagement promotes lymphocyte binding to endothelial cells via a lymphocyte function-associated antigen-1-dependent mechanism. J. Immunol. 165, 5411-5417 (2000).
37. Airas, L. et al. Differential regulation and function of CD73, a glycosyl-phosphatidylinositol-linked 70-kD adhesion molecule, on lymphocytes and endothelial cells. J. Cell Biol. 136, 421-431 (1997).
38. Henttinen, T., Jalkanen, S. & Yegutkin, G. G. Adherent leukocytes prevent adenosine formation and impair endothelial barrier function by ecto-5′-nucleotidase/CD73-dependent mechanism. J. Biol. Chem. 278, 24888-24895 (2003).
39. Kameoka, J., Tanaka, T., Nojima, Y., Schlossman, S. F. & Morimoto, C. Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science 261, 466-469 (1993).
40. Koszalka, P. et al. Targeted disruption of cd73/ecto-5′- nucleotidase alters thromboregulation and augments vascular inflammatory response. Circ. Res. 95, 814-821 (2004). This paper describes the increased attachment of leukocytes to inflamed endothelia in CD73-deficient mice.
41. Goding, J. W., Grobben, B. & Siegers, H. Physiological and pathophysiological functions of the ecto-nucleotide pyrophosphatase/ phosphodiesterase family. Biochim. Biophys. Acta 1638, 1-19 (2003).
42. Tokumura, A. et al. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J. Biol. Chem. 277, 39436-39442 (2002).
43. Clair, T. et al. Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate. Cancer Res. 63, 5446-5453 (2003).
44. Xie, Y. & Meier, K. E. Lysophospholipase D and its role in LPA production. Cell. Signal. 16, 975-981 (2004).
45. Rosen, H. & Goetzl, E. J. Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nature Rev. Immunol. 5, 560-570 (2005).
46. Redegeld, F. A., Caldwell, C. C. & Sitkovsky, M. V. Ecto-protein kinases: ecto-domain phosphorylation as a novel target for pharmacological manipulation? Trends Pharmacol. Sci. 20, 453-459 (1999).
47. Yegutkin, G. G., Henttinen, T., Samburski, S. S., Spychala, J. & Jalkanen, S. The evidence for two opposite, ATP-generating and ATP-consuming, extracellular pathways on endothelial and lymphoid cells. Biochem. J. 367, 121-128 (2002).
48. Deaglio, S., Mehta, K. & Malavasi, F. Human CD38: a (r)evolutionary story of enzymes and receptors. Leuk. Res. 25, 1-12 (2001).
49. Wilson, H. L. et al. ADP-ribosyl cyclase and cyclic ADP-ribose hydrolase act as a redox sensor. A primary role for cyclic ADP-ribose in hypoxic pulmonary vasoconstriction. J. Biol. Chem. 276, 11180-11188 (2001).
50. Lee, H. C. Physiological functions of cyclic ADP-ribose and NAADP as calcium messengers. Annu. Rev. Pharmacol. Toxicol. 41, 317-345 (2001).
51. Guse, A. H. Biochemistry, biology, and pharmacology of cyclic adenosine diphosphoribose (cADPR). Curr. Med. Chem. 11, 847-855 (2004).
52. Sánchez-Madrid, F. & del Pozo, M. A. Leukocyte polarization in cell migration and immune interactions. EMBO J. 18, 501-511 (1999).
53. Li, Z. et al. Roles of PLC-β2 and -β3 and PI3Kγ in chemoattractant-mediated signal transduction. Science 287, 1046-1049 (2000).
54. Dransfield, I., Cabanas, C., Craig, A. & Hogg, N. Divalent cation regulation of the function of the leukocyte integrin LFA-1. J. Cell Biol. 116, 219-226 (1992).
55. 2 integrin? Nature Med. 8, 307 (2002).
56. Partida-Sanchez, S. et al. Regulation of dendritic cell trafficking by the ADP-ribosyl cyclase CD38: impact on the development of humoral immunity. Immunity 20, 279-291 (2004). The importance of CD38 in DC trafficking was uncovered by this elegant study.
57. 2+ level and motility of lymphokine-activated killer cells. J. Biol. Chem. 280, 2888-2895 (2005).
58. + lymphocytes. Role of the human CD38 molecule. J. Immunol. 153, 952-959 (1994).
59. Deaglio, S. et al. Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member; J. Immunol. 160, 395-402 (1998).
60. Funaro, A. et al. CD157 is an important mediator of neutrophil adhesion and migration. Blood 104, 4269-4278 (2004).
61. Koch-Nolte, F et al. Mouse T cell membrane proteins Rt6-1 and R16-2 are arginine/protein mono(ADPribosyl)transferases and share secondary structure motifs with ADP-ribosylating bacterial toxins. J. Biol. Chem. 271, 7686-7693 (1996).
62. Haag, F., Koch-Nolte, F., Kuhl, M., Lorenzen, S. & Thiele, H. G. Premature stop codons inactivate the RT6 genes of the human and chimpanzee species. J. Mol. Biol. 243, 537-546 (1994).
63. Nemoto, E., Yu, Y. & Dennert, G. Cell surface ADP-ribosyltransferase regulates lymphocyte function-associated molecule-1 (LFA-1) function in T cells. J. Immunol. 157, 3341-3349 (1996).
64. Okamoto, S., Azhipa, O., Yu, Y., Russo, E. & Dennert, G. Expression of ADP-ribosyltransferase on normal T lymphocytes and effects of nicotinamide adenine dinucleotide on their function. J. Immunol. 160, 4190-4198 (1998).
65. Han, M. K., Cho, Y. S., Kim, Y. S., Yim, C. Y. & Kim, U. H. Interaction of two classes of ADP-ribose transfer reactions in immune signaling. J. Biol. Chem. 275, 20799-20805 (2000).
66. 7 purinoceptor. Immunity 19, 571-582 (2003).
67. Adriouch, S. et al. A natural P451L mutation in the cytoplasmic domain impairs the function of the mouse P2X- receptor. J. Immunol. 169, 4108-4112 (2002).
68. Ohlrogge, W. et al. Generation and characterization of ecto-ADP-ribosyltransferase ART2.1/ART2.2-deficient mice. Mol. Cell. Biol. 22, 7535-7542 (2002).
69. Struyf, S., Proost, P. & Van Damme, J. Regulation of the immune response by the interaction of chemokines and proteases. Adv. Immunol. 81, 1-44 (2003).
70. De Meester, I., Korom, S., Van Damme, J. & Scharpe, S. CD26, let it cut or cut it down. Immunol. Today 20, 367-375 (1999).
71. Lambeir, A. M. et al. Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family. J. Biol. Chem. 276, 29839-29845 (2001).
72. Christopherson, K. W. 2nd, Cooper, S. & Broxmeyer, H. E. Cell surface peptidase CD26/DPPIV mediates G-CSF mobilization of mouse progenitor cells. Blood 101, 4680-4686 (2003).
73. Ludwig, A., Schiemann, F., Mentlein, R., Lindner, B. & Brandt, E. Dipeptidyl peptidase IV (CD26) on T cells cleaves the CXC chemokine CXCL11 (I-TAC) and abolishes the stimulating but not the desensitizing potential of the chemokine. J. Leukoc. Biol. 72, 183-191 (2002).
74. Shioda, T. et al. Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1α (SDF-1α) and SDF-1β are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage. Proc. Natl Acad. Sci. USA 95, 6331-6336 (1998).
75. Oravecz, T. et al. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J. Exp. Med. 186, 1865-1872 (1997).
76. Iwata, S. et al. CD26/dipeptidyl peptidase IV differentially regulates the chemotaxis of T cells and monocytes toward RANTES: possible mechanism for the switch from innate to acquired immune response. Int. Immunol. 11, 417-426 (1999).
77. Kruschinski, C. et al. CD26 (dipeptidyl-peptidase IV)-dependent recruitment of T cells in a rat asthma model. Clin. Exp. Immunol. 139, 17-24 (2005).
78. Busso, N. et al. Circulating CD26 is negatively associated with inflammation in human and experimental arthritis. Am. J. Pathol. 166, 433-442 (2005).
79. + exchanger isoform NHE3 regulates invasion of human 1-LN prostate tumor cells. J. Biol. Chem. 280, 27173-27178 (2005).
80. Ikushima, H. et al. Soluble CD26/dipeptidyl peptidase IV enhances transendothelial migration via its interaction with mannose 6-phosphate/insulin- like growth factor II receptor. Cell. Immunol. 215, 106-110 (2002).
81. Cheng, H. C., Abdel-Ghany, M., Elble, R. C. & Pauli, B. U. Lung endothelial dipeptidyl peptidase IV promotes adhesion and metastasis of rat breast cancer cells via tumor cell surface-associated fibronectin. J. Biol. Chem. 273, 24207-24215 (1998).
82. Boonacker, E. & Van Noorden, C. J. The multifunctional or moonlighting protein CD26/DPPIV. Eur. J. Cell Biol. 82, 53-73 (2003).
83. Kanayama, N. et al. Inactivation of interleukin-8 by aminopeptidase N (CD13). J. Leukoc. Biol. 57, 129-134 (1995).
84. Shipp, M. A., Stefano, G. B., Switzer, S. N., Griffin, J. D. & Reinherz, E. L. CD10 (CALLA)/neutral endopeptidase 24.11 modulates inflammatory peptide-induced changes in neutrophil morphology, migration, and adhesion proteins and is itself regulated by neutrophil activation. Blood 78, 1834-1841 (1991).
85. Kirkwood, K. S. et al. Deletion of neutral endopeptidase exacerbates intestinal inflammation induced by Clostridium difficile toxin A. Am. J. Physiol. Gastrointest. Liver Physiol. 281, G544-G551 (2001).
86. Blake, G. J. & Ridker, P. M. Novel clinical markers of vascular wall inflammation. Circ. Res. 89, 763-771 (2001).
87. Bazil, V. Physiological enzymatic cleavage of leukocyte membrane molecules. Immunol. Today 16, 135-140 (1995).
88. Smalley, D. M. & Ley, K. L-selectin: mechanisms and physiological significance of ectodomain cleavage. J. Cell. Mol. Med. 9, 255-266 (2005).
89. Peschon, J. J. et al. An essential role for ectodomain shedding in mammalian development. Science 282, 1281-1284 (1998). This report shows that CD156b is a sheddase that cleaves the rolling receptor CD62L from the surface of leukocytes.
90. Mohan, M. J. et al. The tumor necrosis factor-α converting enzyme (TACE): a unique metalloproteinase with highly defined substrate selectivity. Biochemistry 41, 9462-9469 (2002).
91. Walcheck, B., Alexander, S. R., St Hill, C. A. & Matala, E. ADAM-17-independent shedding of L-selectin. J. Leukoc. Biol. 74, 389-394 (2003).
92. Faveeuw, C., Preece, G. & Ager, A. Transendothelial migration of lymphocytes across high endothelial venules into lymph nodes is affected by metalloproteinases. Blood 98, 688-695 (2001).
93. Galkina, E. et al. L-selectin shedding does not regulate constitutive T cell trafficking but controls the migration pathways of antigen-activated T lymphocytes. J. Exp. Med. 198, 1323-1335 (2003).
94. Venturi, G. M. et al. Leukocyte migration is regulated by L-selectin endoproteolytic release. Immunity 19, 713-724 (2003).
95. Itoh, Y. & Seiki, M. MT1-MMP: an enzyme with multidimensional regulation. Trends Biochem. Sci. 29, 285-289 (2004).
96. Nakamura, H. et al. Constitutive and induced CD44 shedding by ADAM-like proteases and membrane-type 1 matrix metalloproteinase. Cancer Res. 64, 876-882 (2004).
97. Suenaga, N., Mori, H., Itoh, Y. & Seiki, M. CD44 binding through the hemopexin-like domain is critical for its shedding by membrane-type 1 matrix metalloproteinase. Oncogene 24, 859-868 (2005). In this work, the authors show that the hemopexin domain of MT-MMPs is involved in the shedding of CD44.
98. Vivinus-Nebot, M. et al. Mature human thymocytes migrate on laminin-5 with activation of metalloproteinase-14 and cleavage of CD44. J. Immunol. 172, 1397-1406 (2004).
99. McQuibban, G. A. et al. Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood 100, 1160-1167 (2002).
100. 3CL1-mediated cell-cell adhesion. Blood 102, 1186-1195 (2003).
101. Salmi, M., Kalimo, K. & Jalkanen, S. Induction and function of vascular adhesion protein-1 at sites of inflammation. J. Exp. Med. 178, 2255-2260 (1993).
102. Jaakkola, K. et al. In vivo detection of vascular adhesion protein-1 in experimental inflammation. Am. J. Pathol. 157, 463-471 (2000).
103. Smith, D. J. et al. Cloning of vascular adhesion protein-1 reveals a novel multifunctional adhesion molecule. J. Exp. Med. 188, 17-27 (1998).
104. Klinman, J. P. & Mu, D. Quinoenzymes in biology. Annu. Rev. Biochem. 63, 299-344 (1994).
105. Salmi, M. et al. A cell surface amine oxidase directly controls lymphocyte migration. Immunity 14, 265-276 (2001). This was the first study to show that SSAO activity is required for lymphocyte-endothelial-cell interactions.
106. H2 lymphocytes in inflamed liver: a role for α-4 integrin and vascular adhesion protein-1. Immunity 23, 153-163 (2005).
107. Salmi, M. & Jalkanen, S. A 90-kilodalton endothelial cell molecule mediating lymphocyte binding in humans. Science 257, 1407-1409 (1992).
108. Lalor, P. F. et al. Vascular adhesion protein-1 mediates adhesion and transmigration of lymphocytes on human hepatic endothelial cells. J. Immunol. 169, 983-992 (2002).
109. Yoong, K. F., McNab, G., Hubscher, S. G. & Adams, D. H. Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumor-infiltrating lymphocytes to tumor endothelium in human hepatocellular carcinoma. J. Immunol. 160, 3978-3988 (1998).
110. Tohka, S., Laukkanen, M.-L., Jalkanen, S. & Salmi, M. Vascular adhesion protein 1 (VAP-1) functions as a molecular brake during granulocyte rolling and mediates their recruitment in vivo. FASEB J. 15, 373-382 (2001).
111. Martelius, T. et al. Blockade of vascular adhesion protein-1 inhibits lymphocyte infiltration in rat liver allograft rejection. Am. J. Pathol. 165, 1993-2001 (2004).
112. Merinen, M. et al. Vascular adhesion protein-1 is involved in both acute and chronic inflammation in the mouse. Am. J. Pathol. 166, 793-800 (2005).
113. Koskinen, K. et al. Granulocyte transmigration through endothelium is regulated by the oxidase activity of vascular adhesion protein-1 (VAP-1). Blood 103, 3388-3395 (2004).
114. Stolen, C. M. et al. Semicarbazide sensitive amine oxidase overexpression has dual consequences: insulin mimicry and diabetes-like complications. FASEB J. 18, 702-704 (2004).
115. Airenne, T. T. et al. Crystal structure of the human vascular adhesion protein-1 : unique structural features with functional implications. Protein Sci. 14, 1964-1974 (2005).
116. O'Sullivan, J. et al. The inhibition of semicarbazide-sensitive amine oxidase by aminohexoses. Biochim. Biophys. Acta 1647, 367-371 (2003).
117. Reth, M. Hydrogen peroxide as second messenger in lymphocyte activation. Nature Immunol. 3, 1129-1134 (2002).
118. Nathan, C. Specificity of a third kind: reactive oxygen and nitrogen intermediates in cell signaling. J. Clin. Invest. 111, 769-778 (2003).
119. Johnston, B., Kanwar, S. & Kubes, P. Hydrogen peroxide induces leukocyte rolling: modulation by endogenous antioxidant mechanisms including NO. Am. J. Physiol. 271, H614-H621 (1996).
120. Willam, C., Schindler, R., Frei, U. & Eckardt, K. U. Increases in oxygen tension stimulate expression of ICAM-1 and VCAM-1 on human endothelial cells. Am. J. Physiol. 276, H2044-H2052 (1999).
121. Saccani, A. et al. Redox regulation of chemokine receptor expression. Proc. Natl Acad. Sci. USA 97, 2761-2766 (2000).
122. 2 activates pro-matrix metalloproteinase-2 through receptor tyrosine kinases/phosphatidylinositol 3-kinase/NF-κB pathway. J. Biol. Chem. 277, 30271-30282 (2002).
123. Deem, T. L. & Cook-Mills, J. M. Vascular cell adhesion molecule 1 (VCAM-1) activation of endothelial cell matrix metalloproteinases: role of reactive oxygen species. Blood 104, 2385-2393 (2004).
124. Yegutkin, G. G., Henttinen, T. & Jalkanen, S. Extracellular ATP formation on vascular endothelial cells is mediated by ecto-nucleotide kinase activities via phosphotransfer reactions. FASEB J. 15, 251-260 (2001).
125. Schwartz, B., Olgin, A. K. & Klinman, J. P. The role of copper in topa quinone biogenesis and catalysis, as probed by azide inhibition of a copper amine oxidase from yeast. Biochemistry 40, 2954-2963 (2001).
126. Krebs, C. et al. CD38 controls ADP-ribosyltransferase-2-catalyzed ADP-ribosylation of T cell surface proteins. J. Immunol. 174, 3298-3305 (2005).
127. Peola, S. et al. Selective induction of CD73 expression in human lymphocytes by CD38 ligation: a novel pathway linking signal transducers with ecto-enzyme activities. J. Immunol. 157, 4354-4362 (1996).
128. Deterre, P. et al. Coordinated regulation in human T cells of nucleotide-hydrolyzing ecto-enzymatic activities, including CD38 and PC-1. Possible role in the recycling of nicotinamide adenine dinucleotide metabolites. J. Immunol. 157, 1381-1388 (1996).
129. Vainio, P. J. et al. Safety of blocking vascular adhesion protein-1 in patients with contact dermatitis. Basic Clin. Pharmacol. Toxicol. 96, 429-435 (2005).
130. Cannon, R. Mechanisms, management and future directions for reperfusion injury after acute myocardial infarction. Nature Clin. Pract. Cardiovasc. Med. 2, 88-94 (2005).
131. Kupatt, C. et al. ACE-inhibition prevents postischemic coronary leukocyte adhesion and leukocyte-dependent reperfusion injury. Cardiovasc. Res. 36, 386-395 (1997).
132. Riaz, A. A. et al. Role of angiotensin II in ischemia/reperfusion-induced leukocyte-endothelium interactions in the colon. FASEB J. 18, 881-883 (2004).
133. Schumacher, M. et al. Primary structure of Torpedo californica acetylcholinesterase deduced from its cDNA sequence. Nature 319, 407-409 (1986).
134. Goding, J. W. Ecto-enzymes: physiology meets pathology. J. Leukoc. Biol. 67, 285-311 (2000).
135. Cheng, H. C., Abdel-Ghany, M., Zhang, S. & Pauli, B. U. Is the Fischer 344/CRJ rat a protein-knock-out model for dipeptidyl peptidase IV-mediated lung metastasis of breast cancer? Clin. Exp. Metastasis 17, 609-615 (1999).